|
EVIDENCE
WATCH
A review and assessment of recent
clinical trial data
Contributors
were selected by Hagen Kennecke, MD, FRCPC and Joseph Ragaz,
MD, FRCPC.
|
To view the clinical trial data of the following topics click
here (pdf format)
Bevacizumab
in colon cancer
Stephen Welch, MD, FRCPC, Assistant Professor,
Department of Oncology, University of Western Ontario; Medical Oncologist,
London Regional Cancer Program, London, ON
Wolmark N, Yothers
G, O’Connell MJ et al. A phase III trial comparing
mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma
of the colon: Results of NSABP Protocol C-08. ASCO 2009, Abstract
LBA4.
Trastuzumab
in advanced gastric cancer
Scot Dowden, MD, FRCPC, Medical Oncologist,
Director; Clinical Assistant Professor and Medical Oncology Training
Program, University of Calgary; Deputy Chair, Gastrointestinal Tumor
Program, Southern Alberta
Van Cutsem E,
Y. Kang Y, H. Chung H et al. Efficacy results from the
ToGA trial: A phase III study of trastuzumab added to standard chemotherapy
(CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive
advanced gastric cancer (GC). ASCO 2009, LBA4509.
Treatment
of triple-negative/BRCA1-associated breast cancer
Debjani Grenier, MD, FRCPC, Medical Oncologist,
CancerCare Manitoba, St. Boniface General Hospital; Assistant Professor,
University of Manitoba, Winnipeg, MB.
O’Shaughnessy
J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly
(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with
gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative
breast cancer (TNBC): results of a randomized phase II trial. ASCO
2009, Abstract 3.
Gronwald J,
Byrski T, Huzarski T et al. Neoadjuvant therapy with cisplatin
in BRCA1-positive breast cancer patients. ASCO 2009, Abstract 502.
Receptor
crosstalk in metastatic breast cancer
Caroline Lohrisch,
MD, FRCPC, Medical Oncologist, British Columbia Cancer Agency, Vancouver,
BC Carlson RW, O’Neill A, Vidaurre T et al. Randomized
phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal,
metastatic breast cancer. ASCO 2009, Abstract 1013.
Cristofanilli
M, Schiff R, Valero V et al. Exploratory subset analysis
according to prior endocrine treatment of two randomized phase II
trials comparing gefitinib (G) with placebo (P) in combination with
tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+)
metastatic breast cancer (MBC). ASCO 2009, Abstract 1014.
Bevacizumab
in metastatic breast cancer
Susan Dent,
MD, BSc, FRCPC, Ottawa Hospital Cancer Centre, Associate Professor
of Medicine, University of Ottawa, ON Robert NJ, Dieras V, J. Glaspy
J et al. RIBBON-1: Randomized, double-blind, placebo-controlled,
phase III trial of chemotherapy with or without bevacizumab (B)
for first-line treatment of HER2-negative locally recurrent or metastatic
breast cancer (MBC). ASCO 2009, Abstract 1005.
To view the clinical trial data click
here (pdf format)
|
